Beijing Wantai Biological Pharmacy Enterprise Co. Ltd. Class A

Beijing Wantai Biological Pharmacy Enterprise Co. Ltd. Class A

SSSE:603392
22.20
CNY
-0.29
(-1.29%)
-0.36EPS
34.57BMarket Cap
Mar 25Next Earn

Total Valuation

CNY

As of September 30, 2026, Beijing Wantai Biological Pharmacy Enterprise Co. Ltd. Class A carries a market capitalization of 34.57B, placing it among publicly traded companies globally. Its enterprise value stands at 31.16B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap34.57B
Enterprise Value31.16B

Important Dates

Beijing Wantai Biological Pharmacy Enterprise Co. Ltd. Class A's next confirmed earnings release is scheduled for March 25, 2027.

Earnings Date3/25/2027

Share Statistics

As of September 30, 2026, Beijing Wantai Biological Pharmacy Enterprise Co. Ltd. Class A has 1.26B shares outstanding.

Shares Outstanding1.26B

Valuation Ratios

These figures are as of September 30, 2026. The price-to-sales ratio is 18.38, and the price-to-book ratio stands at 2.97.

PS Ratio18.38
PB Ratio2.97
P/TBV Ratio3.26

Enterprise Valuation

These figures are as of September 30, 2026. The EV/Sales ratio of 16.03 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 31.16B versus a market cap of 34.57B, with the gap driven by net debt and cash on the balance sheet.

EV / Sales16.03

Financial Position

As of September 30, 2026, Beijing Wantai Biological Pharmacy Enterprise Co. Ltd. Class A maintains a current ratio of 4.35, meaning it holds 4.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 2.91, indicating elevated leverage, while an interest coverage ratio of -87.69 demonstrates limited ability to service its debt obligations.

Current Ratio4.35
Quick Ratio2.57
Debt / Equity2.91
Debt / EBITDA-0.67
Interest Coverage-87.69

Financial Efficiency

CNY

These figures cover the twelve months ended September 30, 2026. The company generates approximately 472,095.58 in revenue per employee across its workforce of 4,116.00, a quick read on workforce productivity versus industry peers.

Revenue Per Employee472,095.58
Employee Count4,116.00

Taxes

CNY

Over the twelve months ended September 30, 2026, Beijing Wantai Biological Pharmacy Enterprise Co. Ltd. Class A recorded an income tax benefit of -53.56M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -525.57M and -455.62M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

Income Tax-53.56M

Stock Price Statistics

CNY

As of the close on November 17, 2026, Beijing Wantai Biological Pharmacy Enterprise Co. Ltd. Class A's stock has declined approximately 59.69% over the past 52 weeks. The 50-day moving average sits at 25.55, while the 200-day moving average is 33.11.

52-Week Price Change-59.69%
50-Day Moving Average25.55
200-Day Moving Average33.11

Income Statement

CNY

Over the twelve months ended September 30, 2026, Beijing Wantai Biological Pharmacy Enterprise Co. Ltd. Class A generated 1.94B in revenue and converted that into -455.62M in net income, yielding earnings per share of -0.36. EBITDA reached -513.01M, while operating income came in at -373.08M.

Revenue1.94B
Gross Profit1.12B
Operating Income-373.08M
Pretax Income-525.57M
Net Income-455.62M
EBITDA-513.01M
EBIT-513.01M
Earnings Per Share (EPS)-0.36

Balance Sheet

CNY

As of September 30, 2026, Beijing Wantai Biological Pharmacy Enterprise Co. Ltd. Class A holds 3.92B in cash and equivalents against 343.18M in total debt, resulting in a net debt position of -2.27B. Total book value stands at 11.63B, with working capital of 5.11B providing operational flexibility.

Cash & Cash Equivalents3.92B
Total Debt343.18M
Net Debt-2.27B
Equity (Book Value)11.63B
Book Value Per Share9.20
Working Capital5.11B

Cash Flow

CNY

These figures cover the twelve months ended September 30, 2026.

Capital Expenditures-599.28M

Margins

Over the twelve months ended September 30, 2026, Beijing Wantai Biological Pharmacy Enterprise Co. Ltd. Class A posted a gross margin of 57.79, reflecting its pricing power and cost economics. The operating margin of -19.20 and net profit margin of -23.45 provide insight into operational efficiency.

Gross Margin57.79
Operating Margin-19.20
Pretax Margin-27.05
Profit Margin-23.45
EBITDA Margin-26.40

Dividends & Yields

Over the twelve months ended September 30, 2026, Beijing Wantai Biological Pharmacy Enterprise Co. Ltd. Class A paid dividends of 0.00 per share. The dividend payout ratio of -0.56 is negative because earnings are negative, so the dividend is being paid out of something other than profits, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield reaches 0.10, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Beijing Wantai Biological Pharmacy Enterprise Co. Ltd. Class A shareholders.

Payout Ratio-0.56
Shareholder Yield0.10

Stock Splits

Beijing Wantai Biological Pharmacy Enterprise Co. Ltd. Class A's most recent stock split took place on June 5, 2023 with a 5:7 split ratio.

Last Split Date6/5/2023
Split Ratio5:7

Scores

As of September 30, 2026, Beijing Wantai Biological Pharmacy Enterprise Co. Ltd. Class A has an Altman Z-Score of 13.08, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score13.08